162 related articles for article (PubMed ID: 21082984)
1. Novel treatment regimens for Waldenström's macroglobulinemia.
García-Sanz R; Ocio EM
Expert Rev Hematol; 2010 Jun; 3(3):339-50. PubMed ID: 21082984
[TBL] [Abstract][Full Text] [Related]
2. Current and future therapeutic approach for Waldenström's macroglobulinemia.
Souchet-Cömpain L; Choquet S; Leblond V; Nguyen S
Immunotherapy; 2014; 6(3):333-48. PubMed ID: 24762077
[TBL] [Abstract][Full Text] [Related]
3. Emerging drugs for Waldenström's macroglobulinemia.
Kastritis E; Terpos E; Dimopoulos MA
Expert Opin Emerg Drugs; 2011 Mar; 16(1):45-57. PubMed ID: 21352069
[TBL] [Abstract][Full Text] [Related]
4. Novel biologically based therapies for Waldenstrom's macroglobulinemia.
Mitsiades CS; Mitsiades N; Richardson PG; Treon SP; Anderson KC
Semin Oncol; 2003 Apr; 30(2):309-12. PubMed ID: 12720159
[TBL] [Abstract][Full Text] [Related]
5. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
Treon SP; Shima Y; Preffer FI; Doss DS; Ellman L; Schlossman RL; Grossbard ML; Belch AR; Pilarski LM; Anderson KC
Semin Oncol; 1999 Oct; 26(5 Suppl 14):97-106. PubMed ID: 10561024
[TBL] [Abstract][Full Text] [Related]
6. [Waldenström's macroglobulinemia].
Poulain S; Wemeau M; Balkaran S; Hivert B; Hautecoeur A; Rossignol J; Fernandez J; Daudignon A; Roumier C; Soenen V; Lepelley P; Lai JL; Morel P; Leleu X
Rev Med Interne; 2010 May; 31(5):385-94. PubMed ID: 20363537
[TBL] [Abstract][Full Text] [Related]
7. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
[TBL] [Abstract][Full Text] [Related]
8. Current treatment options for Waldenström macroglobulinemia.
Vijay A; Gertz MA
Clin Lymphoma Myeloma; 2008 Aug; 8(4):219-29. PubMed ID: 18765309
[TBL] [Abstract][Full Text] [Related]
9. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
10. Novel agents in the treatment of Waldenström's macroglobulinemia.
Treon SP; Hatjiharissi E; Leleu X; Moreau AS; Roccaro A; Hunter ZR; Soumerai JD; Ciccarelli B; Xu L; Sacco A; Ngo HT; Jia X; Yang C; Adamia S; Branagan AR; Ho AW; Santos DD; Tournilhac O; Manning RJ; Leduc R; O'Connor K; Nelson M; Patterson CJ; Ghobrial I
Clin Lymphoma Myeloma; 2007 Aug; 7 Suppl 5():S199-206. PubMed ID: 17877845
[TBL] [Abstract][Full Text] [Related]
11. Waldenström's macroglobulinemia. An overview of its clinical, biochemical, immunological and therapeutic features and our series of 121 patients collected in a single center.
Merchionne F; Procaccio P; Dammacco F
Crit Rev Oncol Hematol; 2011 Oct; 80(1):87-99. PubMed ID: 21036057
[TBL] [Abstract][Full Text] [Related]
12. A safety profile of medications used to treat Waldenström's macroglobulinemia.
García-Sanz R; Jiménez C; González De La Calle V; Sarasquete ME
Expert Opin Drug Saf; 2018 Jun; 17(6):609-621. PubMed ID: 29768934
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and management of Waldenstrom's macroglobulinemia.
Dimopoulos MA; Kyle RA; Anagnostopoulos A; Treon SP
J Clin Oncol; 2005 Mar; 23(7):1564-77. PubMed ID: 15735132
[TBL] [Abstract][Full Text] [Related]
14. Role of proteasome inhibition in Waldenström's macroglobulinemia.
Roccaro AM; Sacco A; Leleu X; Azab AK; Azab F; Runnels J; Jia X; Ngo HT; Melhem M; Moreau AS; Ghobrial IM
Clin Lymphoma Myeloma; 2009 Mar; 9(1):94-6. PubMed ID: 19362985
[TBL] [Abstract][Full Text] [Related]
15. [Complete response achieved after rituximab plus CHOP therapy in a patient with rapidly progressing Waldenstrom's macroglobulinemia].
Ise M; Sakai C; Kumagai K
Rinsho Ketsueki; 2009 Jan; 50(1):34-8. PubMed ID: 19225227
[TBL] [Abstract][Full Text] [Related]
16. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
[TBL] [Abstract][Full Text] [Related]
17. Current options to manage Waldenström's macroglobulinemia.
Benevolo G; Nicolosi M; Santambrogio E; Vitolo U
Expert Rev Hematol; 2017 Jul; 10(7):637-647. PubMed ID: 28592170
[TBL] [Abstract][Full Text] [Related]
18. Waldenström macroglobulinaemia.
Fonseca R; Hayman S
Br J Haematol; 2007 Sep; 138(6):700-20. PubMed ID: 17672883
[TBL] [Abstract][Full Text] [Related]
19. Future directions in immunomodulatory therapy.
Lonial S
Med Oncol; 2010 Jun; 27 Suppl 1():S62-6. PubMed ID: 20012563
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia.
Sun JY; Xu L; Tseng H; Ciccarelli B; Fulciniti M; Hunter ZR; Maghsoudi K; Hatjiharissi E; Zhou Y; Yang G; Zhu B; Liu X; Gong P; Ioakimidis L; Sheehy P; Patterson CJ; Munshi NC; O'Connor OA; Treon SP
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):152-6. PubMed ID: 21454220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]